Key facts
- Sagitta Biotech’s last known valuation is $1.9M (Jul 2025).
- It has raised $700K; the latest was Seed Round ($700K) in Jul 2025.
- Notable investors include Advise Connect Inspire.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Sagitta Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Sagitta Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sagitta Biotech
Developer of viral vectors designed for medical applications. The company specializes in active virosomes based on a modified measles virus, which can be manipulated via a cassette system to express a variety of antigens and payloads, and their platform is available for co-development of custom vaccines, oncology, and gene therapy products as a technology provider or subcontracting partner, enabling people to tackle unmet medical needs in infectious disease and oncology.
- Sector
- Healthcare
- HQ
- Liège, Belgium
- Founded
- 2019
- Employees
- 4
- Website
- sagittabiotech.com/
- Ownership
- Privately Held (backing)
Sagitta Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sagitta Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sagitta Biotech in its N-PORT filings yet. We sweep new filings monthly.